Learning objectives

After completing this module, participants should be able to:

  • Review the results of cardiovascular outcome trials (CVOTs) with SGLT2 inhibitors in people with diabetes, including EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58
  • Asses the results of trials of SGLT2 inhibitors in patients with renal disease, including CREDENCE and DAPA-CKD
  • Asses the results of trials of SGLT2 inhibitors in patients with heart failure, including DAPA-HF and EMPEROR-Reduced
  • Define patients who would benefit from treatment with SGLT2 inhibitors

Faculty

Professor Miles Fisher, Honorary Professor, University of Glasgow, Glasgow

Accreditation

1 CPD/CME credit, 1 hour
BJC Learning has assigned 1 hour of CPD/CME credit to this module

You need to login to take this module

You need to be a registered member to view this page. It’s quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

Source: bjcardio.co.uk

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]